Trump, referring to the Coronavirus at the White House briefing, said, “Today I am happy to make a truly historic declaration in my fight against the China virus as it will save countless lives.” This step will increase access to this treatment. In Geneva, the World Health Organization (WHO) said on Monday that the use of convalescent plasma is still an experimental treatment.
WHO’s chief scientist Soumya Swaminathan said that many clinical trials are still going on worldwide in the context of conjunctive plasma. Swaminathan, India’s pediatrician and top researcher on tuberculosis and HIV, said at the press conference, “Actually, only a few of them have had interim results … and at the moment, the evidence is of very poor quality.” That WHO still believes that plasma therapy is in the experimental phase should be evaluated.
He said that it is difficult to standardize this treatment because antibodies are produced at different levels in people and the plasma should be collected individually from recovered patients. A day before his announcement on plasma treatment, President Trump accused the FDA of obstructing vaccines and treatments for the disease for political reasons. Trump said, “The selfish element or whatever is contained in the FDA is hindering drug companies from testing vaccines or treatments for people.”
“They are obviously looking forward to a delay (until the completion of the US presidential election),” he said. The FDA said in its release that in its effort in the fight against Kovid-19, it had hospitalized Kovid- 19 patients have been approved for their emergency use of plasma for testing purposes. Based on available scientific evidence, the FDA concluded that the product could be effective in the treatment of COVID-19 and that “its known and potential benefits outweigh its known and potential risks.”
According to Johns Hopkins University, more than 1,76,000 people have died due to coronavirus in the US and 57 lakh people have been infected in the country so far. US Health and Human Services Minister Alex Ezar said, “The FDA’s emergency approval for condensed plasma is a major achievement in President Trump’s effort to save lives from COVID-19.” However, many health experts have expressed their reservations about the robustness of the plasma studies conducted so far, including Antony Fossey, a member of the White House workforce on the coronavirus. George Jonathan Reiner, professor (medicine) at George Washington University, said, “The problem is that we don’t have enough data on how effective conjunctive plasma is.”